In the final part of the series, CRA’s Dr. Nick Davies presents an overview of current and emerging analytical tools and explores the opportunities for their use.
Clinical and commercial leaders have made significant investments in data and analytics, fostering an impressive toolkit that can inform development strategy. This paper evaluates each and considers how, collectively, they may inform R&D decisions.
The methods described in this three-part series, enable integrated views into coupled clinical and commercial dynamics to provide consistent, transparent, and useful insight into the drivers of ROIC in R&D. Progress is made when formulating coherent decision rationale based on the current best understanding, and providing testable predictions from which we can learn and improve.
Click here to read more about analytics for clinical development strategy
